

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported		
TITLE	,				
Title	1	Identify the report as a systematic review.	line 2		
ABSTRACT					
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	lines 32-53		
INTRODUCTION					
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	lines 56-70		
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	lines 94-98		
Abstract 2 See the PRISMA 2020 for Abstracts checklist. Inn IntroDUCTION Rationale 3 Describe the rationale for the review in the context of existing knowledge. Inne Cobjectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. Inne Information 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. Inne Information 5 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the Innes sources Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.					
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	line 124,Table 1		
	6		lines 123-124,132		
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	lines 126-132		
Selection process	8		lines 126-132		
	9	independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the	lines 126-132		
Data items	10a		lines 166-187		
	10b		Line 208-231		
	11		Lines 129-132		
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Line 229-231		
	13a		Line 126-132 Table 1		
	13b		Lines 120-134		
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Lines 230-231		
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Line 229-231		
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Line 232-258 -		
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Lines 439-450		
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Lines 302-304		
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Lines 134-138		



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Fig. 1, lines 208-234
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Lines 215-218
Study characteristics	17	Cite each included study and present its characteristics.	Suplemental Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Suplemental table 1
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Suplemental Table 1
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Figs 3, 4, 6
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Table 2
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Lines 259-276
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Lines 259-276
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Lines 304-306
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Lines 451-456
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Lines 198-501
	23b	Discuss any limitations of the evidence included in the review.	Lines 198-501
	23c	Discuss any limitations of the review processes used.	lines 451-456
	23d	Discuss implications of the results for practice, policy, and future research.	Lines 458-501
OTHER INFORMA	TION		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Not registered
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	otocol not prepared
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	none
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	n funding statement
Competing interests	26	Declare any competing interests of review authors.	None
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplemental Table 1, R- script

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/